XML 52 R30.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2021202020212020
Segment Net Sales    
United States$753.3 $662.0 $2,223.7 $1,845.6 
Europe268.9 241.5 806.1 695.9 
Japan126.2 109.9 384.6 325.0 
Rest of World136.1 115.2 393.6 323.4 
Total segment net sales$1,284.5 $1,128.6 $3,808.0 $3,189.9 
Segment Operating Income    
United States$527.4 $453.8 $1,544.1 $1,264.0 
Europe140.6 124.2 426.5 356.2 
Japan83.7 69.2 258.3 209.9 
Rest of World49.5 35.6 145.2 105.2 
Total segment operating income$801.2 $682.8 $2,374.1 $1,935.3 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2021202020212020
Net Sales Reconciliation    
Segment net sales$1,284.5 $1,128.6 $3,808.0 $3,189.9 
Foreign currency25.7 12.3 94.8 4.7 
Consolidated net sales$1,310.2 $1,140.9 $3,902.8 $3,194.6 
Pre-tax Income Reconciliation    
Segment operating income$801.2 $682.8 $2,374.1 $1,935.3 
Unallocated amounts:    
Corporate items(413.6)(331.9)(1,178.7)(1,005.6)
Intellectual property litigation expenses, net(4.7)(8.4)(13.5)(400.8)
Change in fair value of contingent consideration liabilities(1.1)9.0 106.0 (8.4)
Foreign currency8.5 6.3 28.0 25.7 
Consolidated operating income390.3 357.8 1,315.9 546.2 
Non-operating income 0.6 6.5 9.8 14.4 
Consolidated pre-tax income$390.9 $364.3 $1,325.7 $560.6 
Enterprise-Wide Information
The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2021202020212020
Net Sales by Geographic Area    
United States$753.2 $662.0 $2,223.6 $1,845.6 
Europe291.1 253.8 880.9 707.8 
Japan125.9 113.9 390.0 330.7 
Rest of World140.0 111.2 408.3 310.5 
$1,310.2 $1,140.9 $3,902.8 $3,194.6 
Net Sales by Major Product Area    
Transcatheter Aortic Valve Replacement$857.8 $744.6 $2,551.0 $2,081.1 
Transcatheter Mitral and Tricuspid Therapies22.3 12.1 60.7 28.7 
Surgical Structural Heart217.4 203.3 667.8 557.6 
Critical Care212.7 180.9 623.3 527.2 
$1,310.2 $1,140.9 $3,902.8 $3,194.6 

 September 30, 2021December 31, 2020
Long-lived Tangible Assets by Geographic Area  
United States$1,132.9 $1,084.3 
Europe203.8 192.7 
Japan14.6 20.4 
Rest of World330.9 311.0 
$1,682.2 $1,608.4